Latest news with #ConvaTec
Business Insider
28-06-2025
- Business
- Business Insider
Berenberg Bank Sticks to Their Buy Rating for ConvaTec (CTEC)
In a report released yesterday, Sam England from Berenberg Bank maintained a Buy rating on ConvaTec (CTEC – Research Report), with a price target of £3.35. The company's shares closed yesterday at p289.20. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter England covers the Healthcare sector, focusing on stocks such as Carl Zeiss Meditec, Qiagen, and Smith & Nephew Snats. According to TipRanks, England has an average return of -1.7% and a 51.35% success rate on recommended stocks. Currently, the analyst consensus on ConvaTec is a Strong Buy with an average price target of p322.90, representing an 11.65% upside. In a report released on June 26, Barclays also maintained a Buy rating on the stock with a £3.25 price target. The company has a one-year high of p311.20 and a one-year low of p211.80. Currently, ConvaTec has an average volume of 6.48M.
Cision Canada
18-06-2025
- Business
- Cision Canada
Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026
COPENHAGEN, Denmark, June 18, 2025 /CNW/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend significant time manually flushing IV-lines to clear residual medication from IV lines. The financing round marks the company's first external investment and includes backing from leading healthcare investors, such as the former executive of ConvaTec, members of experienced MedTech family offices, and seasoned angel investors with nursing and clinical backgrounds. "The clinical relevance of Droplet IV's technology is clear," said John Lindskog, former executive of ConvaTec and Cimon Medical. "It fills a critical gap in IV medication safety and efficiency - a long-overdue solution for hospitals worldwide." Droplet IV's total funding now exceeds $5 million, including more than $3 million in non-dilutive grants and previous funding from the BioInnovation Institute, Europe's leading life science accelerator. The company now has the capital needed to complete its final regulatory and clinical milestones and commercial launch the product in both the European and U.S. markets by 2026. "We get inquiries from nurses regularly asking when they can have the product" said Marcus Bech, CEO of Droplet IV. "This funding will enable us to make it available to our customers already next year, and I am I'm incredibly proud to have attracted investors with such deep expertise and commitment to help us fulfill this mission" Automated IV flushing is gaining increased recognition in clinical settings - especially in areas where accurate medication dosing is critical. Yet no streamlined, automatic solutions currently exist. Nurses are often burdened with time-consuming manual flushing procedures that introduce variability and increase the risk of error. "I'm excited to see Droplet IV speeding up access to this much-needed technology," said Lisa Gorski, a leading U.S.-based Key Opinion Leader (KOL) in IV therapy and Clinical Advisor to Droplet IV. "Nurses need simple, reliable tools to ensure safe and consistent flushing without it becoming a daily burden."
Yahoo
18-06-2025
- Business
- Yahoo
Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend significant time manually flushing IV-lines to clear residual medication from IV lines. The financing round marks the company's first external investment and includes backing from leading healthcare investors, such as the former executive of ConvaTec, members of experienced MedTech family offices, and seasoned angel investors with nursing and clinical backgrounds. "The clinical relevance of Droplet IV's technology is clear," said John Lindskog, former executive of ConvaTec and Cimon Medical. "It fills a critical gap in IV medication safety and efficiency - a long-overdue solution for hospitals worldwide." Droplet IV's total funding now exceeds $5 million, including more than $3 million in non-dilutive grants and previous funding from the BioInnovation Institute, Europe's leading life science accelerator. The company now has the capital needed to complete its final regulatory and clinical milestones and commercial launch the product in both the European and U.S. markets by 2026. "We get inquiries from nurses regularly asking when they can have the product" said Marcus Bech, CEO of Droplet IV. "This funding will enable us to make it available to our customers already next year, and I am I'm incredibly proud to have attracted investors with such deep expertise and commitment to help us fulfill this mission" Automated IV flushing is gaining increased recognition in clinical settings - especially in areas where accurate medication dosing is critical. Yet no streamlined, automatic solutions currently exist. Nurses are often burdened with time-consuming manual flushing procedures that introduce variability and increase the risk of error. "I'm excited to see Droplet IV speeding up access to this much-needed technology," said Lisa Gorski, a leading U.S.-based Key Opinion Leader (KOL) in IV therapy and Clinical Advisor to Droplet IV. "Nurses need simple, reliable tools to ensure safe and consistent flushing without it becoming a daily burden." The strength of the investor group speaks to both the market's unmet need and the innovation behind Droplet IV's platform. Photo - - View original content to download multimedia: SOURCE Droplet IV Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
23-05-2025
- Business
- Business Insider
Goldman Sachs Reaffirms Their Buy Rating on ConvaTec (CTEC)
Goldman Sachs analyst Richard Felton maintained a Buy rating on ConvaTec (CTEC – Research Report) today and set a price target of p330.00. The company's shares closed yesterday at p279.60. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Felton is a 4-star analyst with an average return of 12.4% and a 66.67% success rate. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ConvaTec with a p317.00 average price target. The company has a one-year high of p279.60 and a one-year low of p211.80. Currently, ConvaTec has an average volume of 6.67M.
